Fda

Getty Images

Cashing in on the crisis: More FDA warning letters

By Danielle Masterson

There is currently no cure for coronavirus, however, that hasn’t stopped companies from preying on consumers’ fears, as a new raft of FDA warning letters makes clear.

Getty Images

Industry stakeholders lay out safety, regulatory challenges

By Danielle Masterson

The Natural Products Association (NPA) recently held a webinar on political and legislative insights. At the forefront — the expansion of health savings accounts, new dietary new dietary ingredient enforcement, DSHEA, accurate labels, and Cannabidiol...

CBD firm CV Sciences reports 11% rise in sales

CBD firm CV Sciences reports 11% rise in sales

By Danielle Masterson

One of the pioneers of the space topped $53 million in annual revenue, but also recorded a loss as the founders cashed out. The firm also said regulatory uncertainty has increased competition as numerous small brands crowd into the field.

FDA photo

Editor's Spotlight

FDA needs new tools in face of CBD explosion, official says

By Hank Schultz

FDA needs new tools to effectively deal with an expanding supplement marketplace, according to agency official Lowell Schiller. This is especially true when contemplating the flood of CBD products, with many more yet to come.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers